Endocrinology & Metabolism Clinical Trials

Statistical methods in endocrinology & metabolism trials

The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.

All endocrinology & metabolism trials

1,009 results

• CTSI Pilot: Improving Adherence to Diabetic Diet: Complete Statistical AnalysisIndependent statistical analysis of CTSI Pilot: Improving Adherence to Diabetic Diet: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04051008).Phase NAResults postedn = 65NCT04051008
• CTSI-PLACEIndependent statistical analysis of A Prospective, Longitudinal Study of Endothelial Function in HIV/HCV Coinfected Subjects: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase NAResults postedn = 87NCT02597790
• Cyproheptadine Hydrochloride and Nutritional Supplementation in Treating Young Patients With Weight Loss With Cancer: Complete Statistical AnalysisIndependent statistical analysis of Cyproheptadine Hydrochloride and Nutritional Supplementation in Treating Young Patients With Weight Loss With Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 2Results postedn = 9NCT00949117
• Cysteamine Eye Drops to Treat Corneal Crystals in Cystinosis: Complete Statistical AnalysisIndependent statistical analysis of Cysteamine Eye Drops to Treat Corneal Crystals in Cystinosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00001213).Phase 2Results postedn = 328NCT00001213
• D&DIndependent statistical analysis of Dyslipidemia and Diabetic Retinopathy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03403283).Phase NAResults postedn = 45NCT03403283
• Daily Versus Alternate Day Iron Supplementation for the Treatment of Iron Deficiency Anemia in Pregnancy: Complete Statistical AnalysisIndependent statistical analysis of Daily Versus Alternate Day Iron Supplementation for the Treatment of Iron Deficiency Anemia in Pregnancy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 4Results postedn = 14NCT04594070
• Dalantercept in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer: Complete Statistical AnalysisIndependent statistical analysis of Dalantercept in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 2Results postedn = 30NCT01720173
• Dalteparin for Primary Venous Thromboembolism (VTE) Prophylaxis in Pancreatic Cancer Patients: Complete Statistical AnalysisIndependent statistical analysis of Dalteparin for Primary Venous Thromboembolism (VTE) Prophylaxis in Pancreatic Cancer Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 4Results postedn = 87NCT00966277
• DAYBREAK: A Study of Setmelanotide in Participants With Specific Gene Variants in the Melanocortin-4 Receptor (MC4R) Pathway: Complete Statistical AnalysisIndependent statistical analysis of DAYBREAK: A Study of Setmelanotide in Participants With Specific Gene Variants in the Melanocortin-4 Receptor (MC4R) Pathway: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 2Results postedn = 164NCT04963231
• Daytime vs. Delayed Eating Among Obese Individuals: Complete Statistical AnalysisIndependent statistical analysis of Daytime vs. Delayed Eating Among Obese Individuals: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03354169).Phase NAResults postedn = 38NCT03354169
• DCCTIndependent statistical analysis of the Diabetes Control and Complications Trial (DCCT), covering its randomized parallel design, insulin behavioral intervention, statistical methodology, planned analysis, and interpretation of the ClinicalTrials.gov record.Phase NAn = 1,441NCT00360815
• DECLARE-TIMI 58Independent statistical analysis of DECLARE-TIMI 58, a completed healthcare-claims replication study comparing dapagliflozin with a DPP-4 inhibitor in diabetes, including its design, composite endpoint, planned time-to-event analysis, and statistical interpretation.n = 49,790NCT04215523
• DelishIndependent statistical analysis of Delish Study: Diabetes Education to Lower Insulin, Sugars, and Hunger: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03207711).Phase NAResults postedn = 60NCT03207711
• DELISH R33Independent statistical analysis of (R33 Phase) DELISH Study: Diabetes Education to Lower Insulin, Sugars, and Hunger: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase NAResults postedn = 125NCT03837405
• DEPICT 1Independent statistical analysis of Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02268214).Phase 3Results postedn = 833NCT02268214
• Depression-Diabetes Mechanisms: Urban African Americans: Complete Statistical AnalysisIndependent statistical analysis of Depression-Diabetes Mechanisms: Urban African Americans: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00209170).Phase 4Results postedn = 20NCT00209170
• Dermatome Electrical Stimulation on Individuals With Overweight and Class I Obesity: Complete Statistical AnalysisIndependent statistical analysis of Dermatome Electrical Stimulation on Individuals With Overweight and Class I Obesity: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase NAResults postedn = 7NCT03261531
• DEVOTEIndependent statistical analysis of DEVOTE (NCT01959529), the double-blind cardiovascular outcomes trial of insulin degludec versus insulin glargine in 7637 people with type 2 diabetes, covering the Cox non-inferiority analysis of MACE, negative…Phase 3Results postedn = 7,637NCT01959529
• DEVOTEIndependent statistical analysis of A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events: primary endpoint results, effect estimate…Phase 3Results postedn = 7,637NCT01959529
• DFUMATIndependent statistical analysis of Improving DFU Outcomes: Early Detection of Foot Ulcers Using Novel Technology: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase NAResults postedn = 20NCT05968924
• Diabetes Prevention Program in Youth: Complete Statistical AnalysisIndependent statistical analysis of Diabetes Prevention Program in Youth: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03042936).Phase NAResults postedn = 33NCT03042936
• Diabetes Prevention Program Lifestyle Intervention in the Marshallese Population: Complete Statistical AnalysisIndependent statistical analysis of Diabetes Prevention Program Lifestyle Intervention in the Marshallese Population: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03270436).Phase NAResults postedn = 380NCT03270436
• Diabetes Prevention Translation: the Healthy Lifestyle Project: Complete Statistical AnalysisIndependent statistical analysis of Diabetes Prevention Translation: the Healthy Lifestyle Project: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01050205).Phase NAResults postedn = 223NCT01050205
• Diabetes Pump With Predictive Low Glucose Suspend Pivotal Trial: Complete Statistical AnalysisIndependent statistical analysis of Diabetes Pump With Predictive Low Glucose Suspend Pivotal Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03195140).Phase NAResults postedn = 103NCT03195140
• DIABETES-PROIndependent statistical analysis of Differing Completion Rates of DIABETES Education on Patient Reported Outcomes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT06419907).Phase NAResults postedn = 120NCT06419907
• Diabetic Foot Ulcer Study Comparing Cytal Wound Matrix 1-Layer to Standard of Care: Complete Statistical AnalysisIndependent statistical analysis of Diabetic Foot Ulcer Study Comparing Cytal Wound Matrix 1-Layer to Standard of Care: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase NAResults postedn = 15NCT03626623
• Diagnostic Accuracy of Shear-Wave Elastography for the Preoperative Risk Stratification of Follicular Lesions of the Thyroid: Complete Statistical AnalysisIndependent statistical analysis of Diagnostic Accuracy of Shear-Wave Elastography for the Preoperative Risk Stratification of Follicular Lesions of the Thyroid: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase NAResults postedn = 35NCT03106337
• Diet as a Potential Treatment for Autosomal Dominant Polycystic Kidney Disease: Complete Statistical AnalysisIndependent statistical analysis of Diet as a Potential Treatment for Autosomal Dominant Polycystic Kidney Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 2/3Results postedn = 34NCT02225860
• Dietary Green Tea Confection For Resolving Gut Permeability-Induced Metabolic Endotoxemia In Obese Adults: Complete Statistical AnalysisIndependent statistical analysis of Dietary Green Tea Confection For Resolving Gut Permeability-Induced Metabolic Endotoxemia In Obese Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase NAResults postedn = 40NCT03413735
• DietGERDIndependent statistical analysis of Dietary Carbohydrate and GERD in Veterans: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02384551).Phase NAResults postedn = 150NCT02384551
• DIPIndependent statistical analysis of Dipeptidyl Peptidase-4 Inhibition in Psoriasis Patients With Diabetes (DIP): A Randomized Clinical Trial.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 2Results postedn = 20NCT01991197
• DIRECTComplete statistical analysis of DIRECT (NCT00252694), a randomized phase 3 trial of candesartan in type 2 diabetes, including trial design, diabetic retinopathy endpoint definition, log-rank analysis, hazard ratio, confidence interval, p-value, and…Phase 3Results postedn = 4,717NCT00252694
• DIRECTComplete statistical analysis of the DIRECT phase 3 trial of candesartan in participants with type 1 diabetes, including trial design, diabetic retinopathy progression, time-to-event methodology, hazard ratio interpretation, and safety.Phase 3Results postedn = 1,850NCT00252720
• DIRECTComplete statistical analysis of the DIRECT trial of candesartan versus placebo in type 1 diabetes, including trial design, ETDRS retinopathy endpoint, log-rank analysis, hazard ratio, confidence interval, p-value, safety, and statistical interpretation.Phase 3Results postedn = 5,238NCT00252733
• DIRECTComplete statistical analysis of DIRECT, a randomized phase 3 trial of denosumab versus placebo in Japanese patients with osteoporosis, including vertebral fracture, non-vertebral fracture, and hip fracture analyses.Phase 3Results postedn = 1,262NCT00680953
• DIVAIndependent statistical analysis of D Vitamin Intervention in VA: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01375660).Phase NAResults postedn = 205NCT01375660
• Docetaxel and Capecitabine in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cavity Cancer: Complete Statistical AnalysisIndependent statistical analysis of Docetaxel and Capecitabine in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cavity Cancer: primary endpoint results, effect estimate with confidence interval,…Phase 2Results postedn = 2NCT00354601
• Does Pioglitazone Increase the Production of 15-EPI-Lipoxin A4?: Complete Statistical AnalysisIndependent statistical analysis of Does Pioglitazone Increase the Production of 15-EPI-Lipoxin A4?: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01040819).Phase 4Results postedn = 25NCT01040819
• Does Ultrasound Improve Procedural Time in the Lateral Popliteal Approach to the Sciatic Nerve in Obese Patients: Complete Statistical AnalysisIndependent statistical analysis of Does Ultrasound Improve Procedural Time in the Lateral Popliteal Approach to the Sciatic Nerve in Obese Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 4Results postedn = 25NCT01579747
• DOPAACRO 002Independent statistical analysis of Assessment of BIM23B065, Given as Repeated Subcutaneous Injection in Subjects With Acromegaly: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 2Results postedn = 4NCT03045302
• Dose Escalation Study MORAb-066 Targeting Tissue Factor (TF)-Expressing Malignancies Including Breast, Pancreatic, Colorectal, NSCLC: Complete Statistical AnalysisIndependent statistical analysis of Dose Escalation Study MORAb-066 Targeting Tissue Factor (TF)-Expressing Malignancies Including Breast, Pancreatic, Colorectal, NSCLC: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 1Results postedn = 27NCT01761240
• Dose Ranging Study Of Bococizumab (PF-04950615; RN316) In Hypercholesterolemic Japanese Subjects: Complete Statistical AnalysisIndependent statistical analysis of Dose Ranging Study Of Bococizumab (PF-04950615; RN316) In Hypercholesterolemic Japanese Subjects: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 2Results postedn = 218NCT02055976
• Dose Titration Investigation of the Pharmacokinetics of Testosterone Transdermal Systems in Hypogonadal Men: Complete Statistical AnalysisIndependent statistical analysis of Dose Titration Investigation of the Pharmacokinetics of Testosterone Transdermal Systems in Hypogonadal Men: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 1Results postedn = 40NCT01104246
• Dose-ranging Efficacy and Pharmacokinetics Study of Intravenous Atorvastatin in Hypercholesterolemic Patients: Complete Statistical AnalysisIndependent statistical analysis of Dose-ranging Efficacy and Pharmacokinetics Study of Intravenous Atorvastatin in Hypercholesterolemic Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 2Results postedn = 40NCT03611010
• Dose-response Study of Paricalcitol Injection in Chronic Kidney Disease Patients Receiving Hemodialysis: Complete Statistical AnalysisIndependent statistical analysis of Dose-response Study of Paricalcitol Injection in Chronic Kidney Disease Patients Receiving Hemodialysis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 2Results postedn = 153NCT00667576
• Double-blind Ipragliflozin Add-on Study in Japanese Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Sitagliptin (MK-0431J-843): Complete Statistical AnalysisIndependent statistical analysis of Double-blind Ipragliflozin Add-on Study in Japanese Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Sitagliptin (MK-0431J-843): primary endpoint results, effect estimate with confidence interval,…Phase 3Results postedn = 143NCT02577003
• Drug-Drug Interaction Study Between AT1001 (Migalastat Hydrochloride) and Agalsidase in Participants With Fabry Disease: Complete Statistical AnalysisIndependent statistical analysis of Drug-Drug Interaction Study Between AT1001 (Migalastat Hydrochloride) and Agalsidase in Participants With Fabry Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 2Results postedn = 20NCT01196871
• DUAL™Independent statistical analysis of A Trial Comparing Sequential Addition of Insulin Aspart Versus Further Dose Increase With Insulin Degludec/Liraglutide in Subjects With Type 2 Diabetes Mellitus, Previously Treated With Insulin Degludec/Liraglutide and…Phase 3Results postedn = 31NCT02100475
• DUAL™ IComplete statistical analysis of DUAL™ I, a randomized phase 3 trial comparing insulin degludec/liraglutide, insulin degludec, and liraglutide in subjects with type 2 diabetes, including ANCOVA, non-inferiority, superiority, confidence intervals, missing-data handling,…Phase 3Results postedn = 1,663NCT01336023
• Duloxetine in Patients With Diabetic in Peripheral Neuropathic Pain With or Without Co-morbid Major Depressive Disorder: Complete Statistical AnalysisIndependent statistical analysis of Duloxetine in Patients With Diabetic in Peripheral Neuropathic Pain With or Without Co-morbid Major Depressive Disorder: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 4Results postedn = 108NCT00844194

← All therapeutic areas